Kisspeptin Protocol
GnRH-signaling neuropeptide studied for reproductive hormone regulation, largely in fertility-research contexts.
- Standard dose
- 0.55 mg
- Frequency
- See product page for frequency
- Route
- Subcutaneous
- Vial
- 5 mg
Evidence Level: Emerging Evidence
Human and/or animal research exists and is accumulating, but the evidence base is not yet as extensive as an approved medicine.
Human evidence: Growing clinical-trial base, particularly in controlled IVF-adjacent research settings.
Animal evidence: Extensive rodent and primate reproductive-endocrinology literature establishing the GnRH-signaling mechanism.
Introduction & Mechanism of Action
GnRH-signaling neuropeptide studied for reproductive hormone regulation, largely in fertility-research contexts.
Upstream regulator of GnRH (gonadotropin-releasing hormone) release from the hypothalamus, positioning it near the top of the reproductive hormone cascade — of particular research interest in IVF-adjacent and fertility contexts.
Receptors/targets: Kisspeptin receptor (KISS1R / GPR54)
Areas of Research Interest
- Reproductive-hormone research
- Fertility-signaling studies
Benefits Reported in Research
- Reproductive-hormone research
- Fertility-signaling studies
Reported Research Dosing Range
The figures below are cited from published research literature and protocol references — they describe what has been studied, not a personal prescription or instruction.
Reported range: 0.1–1 mg
Reported frequency: Structured dosing data unavailable
Reported cycle duration: Structured dosing data unavailable
Escalation & maintenance: A dedicated weekly escalation and maintenance schedule specific to this peptide has not yet been published here — follow the dose range and frequency above, titrating conservatively from the low end, and consult a physician before adjusting.
Research Reference Data
Published research on Kisspeptin reports administration at 0.1–1 mg via subcutaneous route. The table below cites that published research — it is not an individualized instruction.
| Variant | Route | Reported frequency | Reported dose |
|---|---|---|---|
| Standard Protocol | Subcutaneous | See product page for frequency | 0.55 mg |
Reconstitution Reference
Published research protocols reconstitute a 5 mg vial with 2 mL bacteriostatic water, yielding a concentration of 2.50 mg/mL. This is cited reference information, not a personalized preparation instruction — use the general research calculator below for your own reference computation.
Open the research calculator, pre-filled for Kisspeptin →Research Protocol Timeline
A reference summary of how this compound is described across published research — formulation, reported administration, and reported cycle length.
- 01
Formulation
Supplied as a lyophilized 5 mg vial requiring reconstitution before research use.
- 02
Reconstitution Reference
Published research protocols reconstitute this vial with 2 mL bacteriostatic water to reach 2.50 mg/mL.
- 03
Reported Research Administration
Published research describes see product page for frequency administration via subcutaneous route, at 0.55 mg per administration.
Dilution Guide
Reconstitute with 2 mL bacteriostatic water
Bacteriostatic Water (BAC Water) is the only recommended diluent. Do not dilute with sterile water, normal saline, lidocaine, or any other solution unless explicitly specified by the manufacturer.
Handling Guide
General laboratory handling practice cited for reference — not a personalized instruction. Any human use should follow the guidance of a licensed physician.
Wash hands and clean the injection site with an alcohol swab. Pinch a fold of skin and insert the needle at a 45–90° angle for standard subcutaneous injection (abdomen, thigh, or upper arm). Inject slowly, withdraw, and apply gentle pressure. Rotate injection sites to reduce irritation, and dispose of needles in an approved sharps container.
Storage
Store lyophilized (powder) vials in a freezer at -20°C, protected from light. Once reconstituted with bacteriostatic water, refrigerate at 2–8°C and use within the timeframe recommended in your supplier documentation — typically 2–4 weeks.
Monitoring
Monitor for injection-site reactions and the side effects listed above. Stop use and consult a physician if severe or persistent reactions occur. This is a general monitoring guideline, not a personalized medical monitoring plan.
Side Effects
- Injection-site reaction
- Headache (reported in some trial populations)
Contraindications
- Pregnancy (except within a supervised fertility-treatment protocol)
- Hormone-sensitive cancers (theoretical concern)
Drug interactions
- Other fertility-treatment hormones — most human data comes from combination protocols, not standalone use
Safety
- Theoretical risk of ovarian hyperstimulation in fertility-treatment contexts (a known class concern for reproductive-hormone-axis modulators)
Most robust data is from controlled research settings (e.g. IVF-adjacent trials); general therapeutic use is not established.
Expected Results & Comparison
Kisspeptin is grouped in Hormonal & Sexual Wellness for its reproductive-endocrine mechanism, which is mechanistically distinct from Melanotan II's melanocortin-libido pathway and Oxytocin's social-bonding pathway — the three research different parts of hormonal/sexual-wellness biology rather than competing on the same mechanism.